812834CD-DA8F-4C0C-A49E-31D4A882D0E0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.541392904073588
- age_years
- 60
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.599
- MYC_TARGETS_V1+0.585
- DNA_REPAIR+0.537
- MYC_TARGETS_V2+0.503
- G2M_CHECKPOINT+0.496
- INTERFERON_ALPHA_RESPONSE+0.495
- INTERFERON_GAMMA_RESPONSE+0.491
- NOTCH_SIGNALING+0.485
- OXIDATIVE_PHOSPHORYLATION+0.484
- MTORC1_SIGNALING+0.403
Top 10 suppressed
- KRAS_SIGNALING_DN-0.453
- MYOGENESIS-0.270
- SPERMATOGENESIS-0.213
- APICAL_SURFACE-0.134
- HEDGEHOG_SIGNALING-0.112
- ESTROGEN_RESPONSE_EARLY-0.109
- APICAL_JUNCTION-0.052
- PANCREAS_BETA_CELLS-0.019
- COAGULATION-0.010
- UV_RESPONSE_DN+0.001
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C14BEAAE-A766-4ADE-A9B4-674D8717591F | — | — | 0.970 |
| 2 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.961 |
| 3 | D9385661-DBBA-4AF7-B7E6-857BF84CF7CD | — | — | 0.958 |
| 4 | 24E79135-8904-49F9-A748-AC059F325450 | — | — | 0.956 |
| 5 | E97A62A3-E4D3-435C-9165-C0075358578E | — | — | 0.954 |
| 6 | 6B8CAF74-45C6-4C20-8126-A99F73346198 | — | — | 0.952 |
| 7 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.952 |
| 8 | 2E040577-EA0C-4876-9F43-A180DA38F733 | — | — | 0.952 |
| 9 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.952 |
| 10 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.948 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.599 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.585 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.537 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.503 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.496 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.495 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.491 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.485 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.484 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.403 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.352 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.337 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.332 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.304 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.299 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.274 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.269 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.269 | Inavolisib | — uncovered |